Identification of Mitophagy-Associated Genes for the Prediction of Metabolic Dysfunction-Associated Steatohepatitis Based on Interpretable Machine Learning Models

被引:0
|
作者
Deng, Beiying [1 ,2 ]
Chen, Ying [1 ,2 ]
He, Pengzhan [1 ,2 ]
Liu, Yinghui [3 ]
Li, Yangbo [1 ,2 ]
Cai, Yuli [4 ]
Dong, Weiguo [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, 99 Zhangzhidong Rd, Wuhan 430060, Hubei, Peoples R China
[2] Wuhan Univ, Cent Lab, Renmin Hosp, Wuhan, Peoples R China
[3] Wuhan Univ, Dept Geriatr, Renmin Hosp, Wuhan, Peoples R China
[4] Wuhan Univ, Renmin Hosp, Dept Endocrinol, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
metabolic dysfunction-associated steatohepatitis; mitophagy; biomarkers; diagnostic model; machine learning; MITOCHONDRIAL DYSFUNCTION; HEPATOCELLULAR-CARCINOMA; LIVER;
D O I
10.2147/JIR.S450471
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: This study aims to elucidate the role of mitochondrial autophagy in metabolic dysfunction-associated steatohepatitis (MASH) by identifying and validating key mitophagy-related genes and diagnostic models with diagnostic potential. Methods: The gene expression profiles and clinical information of MASH patients and healthy controls were obtained from the Gene Expression Omnibus database (GEO). Limma and functional enrichment analysis were used to identify the mitophagy-related differentially expressed genes (mito-DEGs) in MASH patients. Machine learning models were used to select key mito-DEGs and evaluate their efficacy in the early diagnosis of MASH. The expression levels of the key mito-DEGs were validated using datasets and cell models. A nomogram was constructed to assess the risk of MASH progression based on the expression of the key mito-DEGs. The mitophagy-related molecular subtypes of MASH were evaluated. Results: Four mito-DEGs, namely MRAS, RAB7B, RETREG1, and TIGAR were identified. Among the machine learning models employed, the Support Vector Machine demonstrated the highest AUC value of 0.935, while the Light Gradient Boosting model exhibited the highest accuracy (0.9189), kappa (0.7204), and F1-score (0.9508) values. Based on these models, MRAS, RAB7B, and RETREG1 were selected for further analysis. The logistic regression model based on these genes could accurately predict MASH diagnosis. The nomogram model based on these DEGs exhibited excellent prediction performance. The expression levels of the three mito-DEGs were validated in the independent datasets and cell models, and the results were found to be consistent with the findings obtained through bioinformatics analysis. Furthermore, our findings revealed significant differences in gene expression patterns, immune characteristics, biological functions, and enrichment pathways between the mitophagy-related molecular subtypes of MASH. Subtype-specific small-molecule drugs were identified using the CMap database. Conclusion: Our research provides novel insights into the role of mitophagy in MASH and uncovers novel targets for predictive and personalized MASH treatments.
引用
收藏
页码:2711 / 2730
页数:20
相关论文
共 50 条
  • [31] Monocyte bioenergetics: An immunometabolic perspective in metabolic dysfunction-associated steatohepatitis
    Sangineto, Moris
    Ciarnelli, Martina
    Colangelo, Tommaso
    Moola, Archana
    Bukke, Vidyasagar Naik
    Duda, Loren
    Villani, Rosanna
    Romano, Antonino
    Giandomenico, Stefania
    Kanwal, Hina
    Serviddio, Gaetano
    CELL REPORTS MEDICINE, 2024, 5 (05)
  • [32] Clearance of senescent cells alleviates metabolic dysfunction-associated steatohepatitis
    Sayed, Nilofer
    Chong, Suet Yen
    Ting, Hui Jun
    Zhang, Ziyang
    Li, Phyllis Gan Xiu
    Nagpal, Shakti
    Tan, Michelle Siying
    Tan, De En
    Syn, Nicholas
    Muthiah, Mark
    Dan, Yock Young
    Storm, Gert
    Wang, Jiong Wei
    JOURNAL OF HEPATOLOGY, 2024, 80 : S565 - S566
  • [33] Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma
    Etzion, Ohad
    Bareket-Samish, Avital
    Yardeni, David
    Fishman, Pnina
    BIOMEDICINES, 2024, 12 (04)
  • [34] Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis
    Saeed, Anzel
    Rai, Kuldeep Dalpat
    Saeed, Muzammil
    LIVER RESEARCH, 2024, 8 (03) : 193 - 194
  • [35] Innovative approaches to metabolic dysfunction-associated steatohepatitis diagnosis and stratification
    Matboli, Marwa
    Hamady, Shaimaa
    Saad, Maha
    Khaled, Radwa
    Khaled, Abdelrahman
    Barakat, Eman MF.
    Sayed, Sayed Ahmed
    Agwa, SaraH. A.
    Youssef, Ibrahim
    NON-CODING RNA RESEARCH, 2025, 10 : 206 - 222
  • [36] Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis
    Ramos-Molina, Bruno
    Rossell, Joana
    de Oca, Alejandra Perez-Montes
    Pardina, Eva
    Genua, Idoia
    Rojo-Lopez, Marina I.
    Julian, Maria Teresa
    Alonso, Nuria
    Julve, Josep
    Mauricio, Didac
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [37] A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis
    Shah, Neha
    Sanyal, Arun J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2025, 120 (01): : 75 - 82
  • [38] Mouse models of MetALD and metabolic dysfunction-associated steatohepatitis elicit similar patterns of liver injury
    Lange, Naomi
    Lee, Amani
    Marek, George
    Doskey, Luke
    Daniel, P. Vineeth
    Mauer, Amy
    Shah, Vijay
    Malhi, Harmeet
    JOURNAL OF HEPATOLOGY, 2024, 80 : S134 - S135
  • [39] Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis
    Alexopoulos, Anastasia-Stefania
    Parish, Alice
    Olsen, Maren
    Batch, Bryan C.
    Moylan, Cynthia
    Crowley, Matthew J.
    BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (06)
  • [40] Hepatocellular RECK as a Critical Regulator of Metabolic Dysfunction-associated Steatohepatitis Development
    Dashek, Ryan J.
    Cunningham, Rory P.
    Taylor, Christopher L.
    Alessi, Isabella
    Diaz, Connor
    Meers, Grace M.
    Wheeler, Andrew A.
    Ibdah, Jamal A.
    Parks, Elizabeth J.
    Yoshida, Tadashi
    Chandrasekar, Bysani
    Rector, R. Scott
    CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2024, 18 (03):